Biotech

All Articles

Lykos will ask FDA to reevaluate its selection adhering to turndown of MDMA treatment for trauma

.Adhering to a bad presenting for Lykos Rehabs' MDMA candidate for trauma at a latest FDA advisory c...

AN 2 one-halfs head count, quits stage 3 test after data disappoint

.AN2 Rehabs is actually rethinking its own service in feedback to uninspired midphase data, pledging...

Merck pays for $700M for bispecific, snooping autoimmune opening and possibility to challenge Amgen in cancer

.Merck &amp Co. is paying $700 thousand in advance to challenge Amgen in a blood cancer cells market...

Gilead spends J&ampJ $320M to go out licensing deal for seladelpar

.Along With Gilead Sciences almost an FDA choice for its own liver ailment medicine seladelpar, the ...

' All palms on deck' at Lilly as peers target being overweight market

.CEO David Ricks can see the companies establishing tents at basecamp responsible for Eli Lilly in a...

Entero giving up personnel, leaving workplace and pausing R&ampD

.Mattress Liquidators has turned Entero Rehabs white colored as a slab. The collector got Entero to ...

Exelixis loses ADC after determining it's no match for Tivdak

.Exelixis is losing hope on its own cells variable (TF)- targeting antibody-drug conjugate after con...

Relay loses interest in SHP2 prevention after Genentech leaves behind

.3 full weeks after Roche's Genentech device bowed out an SHP2 prevention pact, Relay Therapeutics h...

Stoke's Dravet syndrome med discharged of partial medical grip

.Stoke Rehabs' Dravet syndrome medication has been freed from a predisposed grip, clearing the metho...

Fierce Biotech's Gabrielle Masson provides Brutal 15 at NYSE

.Strong Biotech Colleague Publisher Gabrielle Masson provided the 2024 class of Brutal 15 victors on...